Latest Paion Ag Aachen (PAIOF) Headlines Seda
Post# of 3
Posted On: 03/10/2014 10:42:49 PM
Latest Paion Ag Aachen (PAIOF) Headlines
Sedation - Pipeline Review, H2 2013
M2 - Mon Nov 25, 2:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mgjcz/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2013" report to their offering. 'Sedation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sedation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sedation. Scope - A snapshot of the global therapeutic scenario for Sedation. - A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sedation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC AcelRx Pharmaceuticals, Inc. PAION AG Novaliq GmbH Maruishi Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/5mgjcz/sedation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Radiation Toxicity Pipeline Review (Radiation Sickness, Acute Radiation Syndrome) - 2013 Edition
M2 - Mon Jun 24, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3jc3b4/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for radiation toxicity , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for radiation toxicity. The report is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: 1. List of Tables/Figures 2. Introduction 2.1 Global Markets Direct Report Coverage 3. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overvi
Hemophilia - Pipeline Review, H1 2013
M2 - Fri Apr 05, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89nnlh/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H1 2013" report to their offering. 'Hemophilia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemophilia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemophilia pipeline depth and focus of Indicatio
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xpq2c2/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). Scope - A snapshot of the global therapeutic scenario for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). - A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under develo
Sedation - Pipeline Review, H2 2013
M2 - Mon Nov 25, 2:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/5mgjcz/sedation) has announced the addition of the "Sedation - Pipeline Review, H2 2013" report to their offering. 'Sedation - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Sedation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sedation. Scope - A snapshot of the global therapeutic scenario for Sedation. - A review of the Sedation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Sedation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC AcelRx Pharmaceuticals, Inc. PAION AG Novaliq GmbH Maruishi Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/5mgjcz/sedation About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Radiation Toxicity Pipeline Review (Radiation Sickness, Acute Radiation Syndrome) - 2013 Edition
M2 - Mon Jun 24, 4:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3jc3b4/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for radiation toxicity , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for radiation toxicity. The report is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: 1. List of Tables/Figures 2. Introduction 2.1 Global Markets Direct Report Coverage 3. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Overvi
Hemophilia - Pipeline Review, H1 2013
M2 - Fri Apr 05, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/89nnlh/hemophilia) has announced the addition of the "Hemophilia - Pipeline Review, H1 2013" report to their offering. 'Hemophilia - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hemophilia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hemophilia. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Hemophilia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Hemophilia pipeline depth and focus of Indicatio
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xpq2c2/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). Scope - A snapshot of the global therapeutic scenario for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). - A review of the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) products under develo
(0)
(0)Paion Ag Aachen (PAIOF) Stock Research Links
Scroll down for more posts ▼